Academic history
Spero Cataland is a Professor of Internal Medicine in the Division of Hematology at the Wexner Medical Center at The Ohio State University, Columbus, OH, and is the Director of the Benign Hematology Program at Ohio State University.
Prof. Cataland received his medical degree at the Ohio State University College of Medicine, Columbus, OH, and subsequently completed a residency in internal medicine at Ohio State University Wexner Medical Center, Columbus, OH, followed by a fellowship in hematology/oncology at the University of Chicago, Chicago, IL. His work has been published in numerous journals, including the New England Journal of Medicine, Blood and the Journal of Thrombosis and Haemostasis.
Speaking on non-malignant blood disorders
Prof. Cataland’s primary research focuses on platelet abnormalities, blood clotting and bleeding disorders. He established the thrombotic microangiopathy research program, which studies rare blood diseases including thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic-uremic syndrome (HUS). Through his research, Prof. Cataland established the role of the metalloprotease ADAMTS13 in TTP and has identified biomarkers that can help diagnose and predict long term complications of TTP.
Prof. Cataland is also involved in several clinical trials, including a Phase III trial investigating the efficacy of caplacizumab in patients with acquired TTP, and a Phase III trial investigating the efficacy and safety of the C5 inhibitor ravulizumab in adult patients with HUS.
